Sava Infond d.o.o. Takes $421,000 Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sava Infond d.o.o. bought a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 3,420 shares of the specialty pharmaceutical company's stock, valued at approximately $421,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IFP Advisors Inc bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $25,000. CoreFirst Bank & Trust bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at $28,000. Jones Financial Companies Lllp lifted its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares in the last quarter. UMB Bank n.a. boosted its holdings in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock worth $38,000 after acquiring an additional 129 shares during the last quarter. Finally, Lindbrook Capital LLC grew its stake in shares of Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock worth $48,000 after acquiring an additional 176 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Performance

JAZZ traded up $2.75 on Tuesday, hitting $126.90. The company's stock had a trading volume of 347,801 shares, compared to its average volume of 736,950. The company's 50 day simple moving average is $132.36 and its 200-day simple moving average is $122.78. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The firm has a market cap of $7.71 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now owns 425,525 shares of the company's stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $137.81, for a total transaction of $157,103.40. Following the completion of the sale, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,736 shares of company stock worth $4,022,825. 4.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on JAZZ shares. HC Wainwright boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Morgan Stanley restated an "overweight" rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday, March 7th. Barclays reaffirmed an "overweight" rating and set a $200.00 price target (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $176.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.